The hepatitis E virus (HEV) is the causative agent of hepatitis E, an acute form of viral hepatitis. The biology and pathogenesis of HEV remain poorly understood. We have used in vitro binding assays to show that the HEV ORF3 protein (pORF3) binds to a number of cellular signal transduction pathway proteins. This includes the protein tyrosine kinases Src, Hck, and Fyn, the p85␣ regulatory subunit of phosphatidylinositol 3-kinase, phospholipase C␥, and the adaptor protein Grb2. A yeast two-hybrid assay was used to further confirm the pORF3-Grb2 interaction. The binding involves a proline-rich region in pORF3 and the src homology 3 (SH3) domains in the cellular proteins. Competition assays and computer-assisted modeling was used to evaluate the binding surfaces and interaction energies of the pORF3⅐SH3 complex. In pORF3-expressing cells, pp60 src was found to associate with an 80-kDa protein, but no activation of the Src kinase was observed in these cells. However, there was increased activity and nuclear localization of ERK in the pORF3-expressing cells. These studies suggest that pORF3 is a viral regulatory protein involved in the modulation of cell signaling. The ORF3 protein of HEV appears to be the first example of a SH3 domain-binding protein encoded by a virus that causes an acute and primarily self-limited infection.Hepatitis E virus (HEV), 1 the causative agent for hepatitis E, is a waterborne pathogen endemic to much of the developing world where it causes rampant sporadic infections and large scale epidemics (1-4). While the infection is self-limited with no associated chronicity, a fraction of the patients progress to fulminant hepatitis (5, 6), the most severe form of acute hepatitis. High mortality rates of 20 -30% reported for HEV infection during pregnancy (7,8) are also the result of fulminant hepatitis. The reasons for this and the mechanisms of viral pathogenesis are not known. The studies on HEV biology and pathogenesis have been severely restricted by the lack of a reliable cell culture system and small animal models of viral infection. We have used subgenomic expression strategies to study the properties and functions of individual HEV gene products toward understanding viral replication and pathogenicity (9 -12).The HEV genome is a ϳ7.5-kilobase polyadenylated, positive-sense RNA that contains three open reading frames (ORFs) designated ORF1, ORF2, and ORF3 (13). The ORF3 of HEV encodes a protein of ϳ13.5 kDa, called pORF3, for which no function has been assigned. When expressed in animal cells, pORF3 is phosphorylated at a single serine residue (Ser 80 ) in its 123-amino acid primary sequence (11). In vitro phosphorylation experiments suggested that pORF3 may be a substrate for the mitogen-activated protein (MAP) kinase, and subcellular fractionation revealed its association with the cytoskeleton (11). Recent results using inhibitors, activators, and dominant negative alleles show that pORF3 is a substrate for the extracellular signal-regulated kinase (ERK) as well as the stressactivated pr...

A lack of molecular understanding of the targets and mechanisms of artemisinin action has impeded the improvisation of more efficient antimalarials based on this class of endoperoxide drugs. We have synthesized a heme-artemisinin adduct designated as "hemart" to discover if it mediates the ability of artemisinin to inhibit heme polymerization. Hemart mimics heme in binding to Plasmodium falciparum histidine-rich protein II (PfHRP II) but cannot self-polymerize. Instead, it inhibits all heme polymerizations, including basal and those triggered by PfHRP II, Monooleoyl glycerol (MOG), or P. yoelii extract. Hemart has an edge over heme in displacing heme from PfHRP II, and either low pH or chloroquine dissociates heme but not hemart from PfHRP II. Our results suggest that hemart, by mimicking heme, stalls all mechanisms of heme polymerization, resulting in the death of the malaria parasite.

Elucidation of the principal targets of the action of the antimalarial drug artemisinin is an ongoing pursuit that is important for understanding the action of this drug and for the development of more potent analogues. We have examined the chemical reaction of Hb with artemisinin. The protein-bound haem in Hb has been found to react with artemisinin much faster than is the case with free haem. It appears that the uptake of Hb and the accumulation of artemisinin into the food vacuole, together with the preferred reactivity of artemisinin with haem in Hb, may make Hb the primary target of artemisinin's antimalarial action. Both monoalkylated (HA) and dialkylated (HAA) haem derivatives of artemisinin have been isolated. These 'haemarts' bind to PfHRP II (Plasmodium falciparum histidine-rich protein II), inhibiting haemozoin formation, and possess a significantly decreased ability to oxidize ascorbic acid. The accelerated formation of HAA from Hb is expected to decrease the ratio of haem to its alkylated derivatives. The haemarts that are generated from 'haemartoglobins' may bring about the death of malaria parasite by a two-pronged effect of stalling the formation of haemozoin by the competitive inhibition of haem binding to its templates and creating a more reducing environment that is not conducive to the formation of haemozoin.

Design of helical super secondary structural motifs is expected to provide important scaffolds to incorporate functional sites, thus allowing the engineering of novel miniproteins with function. An ␣,␤-dehydrophenylalanine containing 21-residue apolar peptide was designed to mimic the helical hairpin motif by using a simple geometrical design strategy. The synthetic peptide folds into the desired structure as assessed crystallographically at 1.0-Å resolution. The two helices of the helical-hairpin motif, connected by a flexible (Gly)4 linker, are docked to each other by the concerted influence of weak interactions. The folding of the peptide without binary patterning of amino acids, disulfide bonds, or metal ions is a remarkable observation. The results demonstrate that preferred interactions among the hydrophobic residues selectively discriminate their putative partners in space, leading to the unique folding of the peptide, also a hallmark of the unique folding of hydrophobic core in globular proteins. We demonstrate here the engineering of molecules by using weak interactions pointing to their possible further exploitation in the de novo design of protein super secondary structural elements. D e novo protein design endeavors to understand the frustrating complexity of protein architecture and has the ambitious goal of constructing novel molecules with predetermined structure and function(s) (1-4). Most design strategies rely on information from the rich database of solved protein structures (5, 6). Further, the observed patterning of polar͞nonpolar residues and their different modes of interaction with the solvent is a major consideration in achieving compaction (1-4, 7). A conceptually distinct approach is to achieve stereochemical control over the local folding of the peptide by incorporation of conformation-restricting residues. For example, ␣,␤-dehydrophenylalanine (⌬Phe) or ␣-aminoisobutyric acid residues nucleate helical conformation whereas D-Pro nucleates hairpins (8-11). The success in establishing these ''folding rules'' has encouraged subsequent attempts to design and construct super secondary structures, in particular, the apparently simple helical hairpin (helix-turn-helix) motif. Many attempts in which designed hydrophobic helices were connected by linker sequences containing various coded͞noncoded amino acids with a tendency to break continuous helix formation, e.g., -aminocaprionic acid, L-lactic acid, Gly-Pro, D-Phe-Pro, and Gly-Dpg, etc., have failed to realize the desired folded conformation (9, 12). Therefore the stabilization of the monomeric helical hairpin motif without binary patterning of polar͞nonpolar residues has proved to be challenging.Our design strategy for stabilization of the helical hairpin motif is based on a shift of paradigm from overemphasis on the linker region (9) toward the optimization of weak interactions between helices (termed long-range interactions). We have used ⌬Phe, the dehydro analogue of phenylalanine, with a double bond between C ␣ and C ␤ atoms, which mak...

Toward delineation of antimicrobial action, a prototypic amphipathic, cationic decapeptide Ac-G-X-R-K-X-H-K-X-W-A-NH(2) was designed and peptides for which X was didehydrophenylalanine (DeltaFm), alpha-aminoisobutyric acid (Um), or phenylalanine (Fm) were synthesized. A growth kinetics experiment indicated that the bacteriostatic effects were nil (Um), mild and transient (Fm), and strong and persistent (DeltaFm) respectively. Though at par in binding to lipopolysaccharide, DeltaFm and Fm, but not Um, caused outer membrane permeabilization. Inner membrane permeabilization was attenuated and membrane architecture rehabilitated with DeltaFm but not Fm. Reverse phase high-performance liquid chromatography revealed that DeltaFm was translocated into Escherichia coli, while Um and fragments of Fm were detected in the medium. Among these monomers, only DeltaFm was modestly antibiotic [minimum inhibitory concentrations (MICs) of 110 microM (E. coli) and 450 microM (Staphylococcus aureus)]. Interestingly, a linear dimer of DeltaFm, viz. (DeltaFm)(2), turned out to be highly potent against E. coli [MIC of 2 microM and minimum bactericidal concentration (MBC) of 2 microM] and modestly potent against S. aureus (MIC of 20 microM and MBC of 20 microM). In contrast, a lysine-based branched dimer of DeltaFm, viz. DeltaFd, was found to be a potent antimicrobial against both E. coli (MIC of 2.5 microM) and S. aureus (MIC of 5 microM). Studies with analogous branched dimers of Fm and Um have indicated that dimerization represents a scaffold for potentiation of antimicrobial peptides and that the presence of DeltaF confers potent activity against both E. coli and S. aureus. De novo design has identified DeltaFd as a potent, noncytotoxic, bacterial cell-permeabilizing and -penetrating antimicrobial peptide, more protease resistant than its monomeric counterpart. We report that in comparison to the subdued and sequential "membrane followed by cell interior" mode of action of the monomeric DeltaFm, the strong and simultaneous "membrane along with cell interior" targeting by the dimeric DeltaFd potentiates and broadens its antibiotic action across the Gram-negative-Gram-positive divide.

Malaria is a major global public health problem, and the alarming spread of drug resistance and limited number of effective drugs now available underline how important it is to discover new antimalarial compounds. In the present study, ten plants were extracted with ethyl acetate and methanol and tested for their antimalarial activity against chloroquine (CQ)-sensitive (3D7) and CQ-resistant (Dd2 and INDO) strains of Plasmodium falciparum in culture using the fluorescence-based SYBR Green assay. Plant extracts showed moderate to good antiparasitic effects. Promising antiplasmodial activity was found in the extracts from two plants, Phyllanthus emblica leaf 50% inhibitory concentration (IC₅₀) 3D7: 7.25 μg/mL (ethyl acetate extract), 3.125 μg/mL (methanol extract), and Syzygium aromaticum flower bud, IC₅₀ 3D7:13 μg/mL, (ethyl acetate extract) and 6.25 μg/mL (methanol extract). Moderate activity (30-75 μg/mL) was found in the ethyl acetate and methanol extracts of Abrus precatorius (seed) and Gloriosa superba (leaf); leaf ethyl acetate extracts of Annona squamosa and flower of Musa paradisiaca. The above mentioned plant extracts were also found to be active against CQ-resistant strains (Dd2 and INDO). Cytotoxicity study with P. emblica leaf and S. aromaticum flower bud, extracts showed good therapeutic indices. These results demonstrate that leaf ethyl acetate and methanol extracts of P. emblica and flower bud extract of S. aromaticum may serve as antimalarial agents even in their crude form. The isolation of compounds from P. emblica and S. aromaticum seems to be of special interest for further antimalarial studies.

Leishmaniasis consists of a complex spectrum of infectious diseases with worldwide distribution of which visceral leishmaniasis or kala-azar caused by Leishmania donovani is the most devastating. In the absence of vaccines, chemotherapy remains the mainstay for the control of leishmaniasis. The drugs of choice are expensive and associated with multiple adverse side effects. Because of these limitations, the development of new antileishmanial compounds is imperative and plants offer prospects in this regard. The present work was conducted to study the antileishmanial potential of oil from Syzygium aromaticum flower buds (clove). The S. aromaticum oil was characterized by gas chromatography and GC-MS and eugenol as well as eugenyl acetate were found to be the most abundant compounds, composing 59.75 % and 29.24 %, respectively of the oil. Our findings have shown that eugenol-rich essential oil from S. aromaticum (EROSA) possesses significant activity against L. donovani, with 50 % inhibitory concentration of 21±0.16 mg ml "1 and 15.24±0.14 mg ml "1 , respectively, against promastigotes and intracellular amastigotes. Alterations in cellular morphology and growth reversibility assay substantiated the leishmanicidal activity of EROSA. The leishmanicidal effect was mediated via apoptosis as confirmed by externalization of phosphatidylserine, DNA nicking by TdT-mediated dUTP nick-end labelling (TUNEL) assay, dyskinetoplastidy, cell cycle arrest at sub-G 0 -G 1 phase, loss of mitochondrial membrane potential and reactive oxygen species generation. EROSA presented no adverse cytotoxic effects against murine macrophages even at 200 mg ml "1 . Our studies authenticate the promising antileishmanial activity of EROSA, which is mediated by programmed cell death, and, accordingly, EROSA may be a source of novel agents for the treatment of leishmaniasis.

By choosing membranes as targets of action, antibacterial peptides offer the promise of providing antibiotics to which bacteria would not become resistant. However, there is a need to increase their potency against bacteria along with achieving a reduction in toxicity to host cells. Here, we report that three de novo-designed antibacterial peptides (⌬Fm, ⌬Fmscr, and Ud) with poor to moderate antibacterial potencies and kill kinetics improved significantly in all of these aspects when synergized with rifampin and kanamycin against Escherichia coli. (⌬Fm and ⌬Fmscr [a scrambled-sequence version of ⌬Fm] are isomeric, monomeric decapeptides containing the nonproteinogenic amino acid ␣,␤-didehydrophenylalanine [⌬F] in their sequences. Ud is a lysine-branched dimeric peptide containing the helicogenic amino acid ␣-aminoisobutyric acid [Aib].) In synergy with rifampin, the MIC of ⌬Fmscr showed a 34-fold decrease (67.9 g/ml alone, compared to 2 g/ml in combination). A 20-fold improvement in the minimum bactericidal concentration of Ud was observed when the peptide was used in combination with rifampin (369.9 g/ml alone, compared to 18.5 g/ml in combination). Synergy with kanamycin resulted in an enhancement in kill kinetics for ⌬Fmscr (no killing until 60 min for ⌬Fmscr alone, versus 50% and 90% killing within 20 min and 60 min, respectively, in combination with kanamycin). Combination of the dendrimeric peptide ⌬Fq (a K-K2 dendrimer for which the sequence of ⌬Fm constitutes each of the four branches) (MIC, 21.3 g/ml) with kanamycin (MIC, 2.1 g/ml) not only lowered the MIC of each by 4-fold but also improved the therapeutic potential of this highly hemolytic (37% hemolysis alone, compared to 4% hemolysis in combination) and cytotoxic (70% toxicity at 10؋ MIC alone, versus 30% toxicity in combination) peptide. Thus, synergy between peptide and nonpeptide antibiotics has the potential to enhance the potency and target selectivity of antibacterial peptides, providing regimens which are more potent, faster acting, and safer for clinical use.